Transcriptional Regulation in the Mouse Atrioventricular Conduction System
- Derek J. Chadwick Organizer,
- Jamie Goode
Published Online: 7 OCT 2008
DOI: 10.1002/0470868066.ch11
Copyright © Novartis Foundation 2003
Book Title

Development of the Cardiac Conduction System: Novartis Foundation Symposium 250
Additional Information
How to Cite
Edwards, A. V., Davis, D. L., Juraszek, A. L., Wessels, A. and Burch, J. B. E. (2008) Transcriptional Regulation in the Mouse Atrioventricular Conduction System, in Development of the Cardiac Conduction System: Novartis Foundation Symposium 250 (eds D. J. Chadwick and J. Goode), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470868066.ch11
Publication History
- Published Online: 7 OCT 2008
- Published Print: 20 JUN 2003
ISBN Information
Print ISBN: 9780470850350
Online ISBN: 9780470868065
- Summary
- Chapter
Summary
We identified a GATA6 gene enhancer that selectively marks the developing atrioventricular conduction system (AVCS) in transgenic mice. This enhancer reads anterior/posterior and medial/lateral positional information early in the cardiogenic programme and remains active in progressively more restricted subsets of heart cells leading up to AVCS formation. Additional experiments will be required to determine if the potential to be recruited into the AVCS is similarly restricted to a subset of myocardial cells early in the cardiogenic programme or if this enhancer can also be activated de novo in cells that initially reside outside this field. We are using several strategies to identify factors that regulate this and other AVCS enhancers and hence govern AVCS function. We are also using this enhancer to make transgenic mice that express Cre, or an inducible form of Cre, to track lineages and to delete floxed genes in the developing or mature AVCS. This Cre/lox approach provides a means to deconstruct complex congenital heart phenotypes that involve the conduction system and to test whether genes are required to form the AVCS or to maintain AVCS function. Lastly, we are exploring strategies to isolate and analyse AVCS cells from normal and affected hearts.
